Best Practices for Orange Book Listings
An article authored by Jonathan Roses titled “Best Practices for Orange Book Listings” was published in The Pharma Letter as an “Expert View.” In this article, Jon provides insights into how to succes...
An article authored by Jonathan Roses titled “Best Practices for Orange Book Listings” was published in The Pharma Letter as an “Expert View.” In this article, Jon provides insights into how to succes...
We are pleased to spotlight Patent Agent Roshan Plamthottam this month! Roshan works in the Chemical & Materials Technologies Practice and works out of our Boston office.
(as published in IPWatchdog)
An article authored by Evan Bender, James Morris, and Usha Parker titled “The Ins and Outs of Incorporation by Reference” was published in Intellectual Property & Technology Law Journal. This arti...
We are pleased to spotlight Executive Assistant Katherine (Kathy) Rodriguez this month! Kathy works in the Paralegal and Library Services department and is based in Washington, DC.
Bio/pharma patents are rarely targeted in inter partes review (IPR) proceedings because their technical vulnerabilities often relate to written description and/or enablement. IPR, of course, is restri...
On September 21, 2023, the Federal Circuit considered an expectation of success argument in the predictable arts as it related to electro-mechanical assemblies. In Elekta Limited v. Zap Surgical Syste...
“Rapunzel, Rapunzel, let down your hair, so that I may climb thy golden stair . . .”
A column authored by Jason Balich titled “The Billion-Dollar Design” was published in the American Institute of Chemical Engineers’ Chemical Engineering Progress (CEP) Magazine. In this article, Jason...
An article co-authored by Jason Balich and Brandon Blackwell titled “Is Your Company’s NDA Up to Date With Robust IP Provisions?” was published in Corporate Counsel.
An article authored by Scott McKeown titled “New Pair of Federal Circuit Precedents Add Wiggle Room for PTAB Petitioners” was published in IAM. In inter partes review (IPR) proceedings, the scope of a...
Technology companies and manufacturers know that they do not infringe a patent if they (or their products) do not practice a claimed invention. But did you know that there are certain circumstances wh...